Another instance of a targeted therapy in clinical use is everolimus (AfinitorTM); this drug inhibits the mammalian target of rapamycin (mTOR) pathway, which is involved in the regulation of the cell cycle, thereby inhibiting cancer cell growth (56). The gene discussed is MTOR; the disease is cancer.